Compounded GLP-1: 4 Dates, and What Brand Costs Now

Reviewed by the HealthyMag Editorial Team. Every figure below was read from the FDA or the manufacturer’s own page on 10 September 2026, and each one links to the page that publishes it.

Search whether compounded semaglutide is still legal and you will get a page of confident yeses. Look at who is publishing them and a pattern appears immediately: nearly every top result is a telehealth company that sells compounded semaglutide. That is not a reason to disbelieve them, but it is a reason to go and read the primary documents yourself, which is what this page does. We sell nothing here, and we have turned down the affiliate offers in this category, so the answer below costs us nothing to give.

What changed, and exactly when

Compounding a copy of a commercial drug is normally not permitted. The exception that made the GLP-1 boom possible was the drug shortage provision: while a drug sits on the FDA’s shortage list, pharmacies may compound versions of it. Semaglutide and tirzepatide were both on that list, and an entire telehealth industry was built inside that window.

The window closed. The FDA set out four separate wind-down dates, and its page recording them was last updated on 1 April 2026:

The FDA’s own words for each are the same: “the period of enforcement discretion has ended.” It adds that even afterwards it “may still take action regarding violations of any other statutory or regulatory requirements, such as to address findings that a product may be of substandard quality or otherwise unsafe.”

Then it went further. The agency has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list — the list of substances outsourcing facilities are allowed to compound from in bulk — on the finding that there is no clinical need for them to do so. The comment period on that proposal runs to 29 June 2026. Read in sequence, the four dates and the bulks-list proposal are not a pause. They are a wind-down.

What “compounded” actually means, and what the FDA does not do

This is the sentence that most product pages leave out, and the FDA states it plainly: “compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.”

That matters more than it sounds, because of where the evidence comes from. Every trial result you have read about these medicines — the weight-loss percentages, the cardiovascular outcomes, the side-effect profiles — was produced using the approved product, made to a fixed specification in a regulated facility. A compounded version made from bulk semaglutide is a different physical product. It may be excellent. It has not been through the process that produced the numbers being quoted at you.

So when a page cites a landmark trial next to a compounded vial, the citation and the product are not the same thing. That is not a technicality. It is the whole basis on which anyone claims to know what the drug does.

The safety signal, in the FDA’s own counts

Numbers rather than adjectives. As of 31 May 2026 the FDA had received 990 reports of adverse events associated with compounded semaglutide and more than 730 associated with compounded tirzepatide.

Adverse event reports are not proof of causation and the FDA says so. What makes these worth reading is the mechanism behind a specific subset of them. The agency describes “multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products,” and separately notes patients “prescribed compounded semaglutide or tirzepatide products in doses beyond what is in the FDA-approved drug label.”

The approved products are supplied as pens or single-dose vials with the dose fixed for you. Much compounded supply arrives as a multi-dose vial with a syringe and instructions, and the patient draws the dose. Those two facts explain each other. A tenfold error is arithmetically easy when the units on the syringe, the concentration in the vial and the dose in the instructions are three different scales.

The “research use only” trade, which is a separate and worse thing

Compounded medicine from a licensed pharmacy is one category. What is sold online labelled “for research purposes” or “not for human consumption” is another, and it should not be confused with it. The FDA has warned companies that “illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled ‘for research purposes’ or ‘not for human consumption'” while supplying them directly to consumers with dosing instructions.

If a product needs a disclaimer saying it is not for human consumption, alongside instructions telling a human how to consume it, the disclaimer is a legal device rather than a description. Retatrutide, survodutide and mazdutide in particular are investigational compounds. Nobody selling them in a vial has the evidence to tell you what dose is safe, because that evidence does not exist yet.

The reason people chose compounded has mostly closed

Almost every account of why compounded GLP-1s took off comes back to price. That case was strong when the alternative was a list price above $1,000 a month. It is much weaker now, because both manufacturers now sell direct to self-paying patients. These are the companies’ own published prices.

Wegovy (semaglutide), from Novo Nordisk’s NovoCare pharmacy:

Zepbound (tirzepatide) single-dose vials, from Lilly:

Lilly’s own pricing page gives the list price of Zepbound as $499 to $1,086.37 per fill, so the self-pay figures are a real reduction rather than a rebadged list price. Whatever a compounded programme has quoted you, that is now the number to compare it against — and the comparison is no longer between $200 and $1,000.

The 45-day catch in the Lilly price

Here is the detail that is missing from essentially every article about GLP-1 pricing, and it is in Lilly’s own footnote.

The $449 figure for the 7.5 mg, 10 mg, 12.5 mg and 15 mg vials applies “only on first fill and when prescriptions are refilled within 45 days of their previous delivery.” Miss that window and the price reverts. At 12.5 mg that is $849 instead of $449. At 15 mg it is $1,049 instead of $449, which is 2.3 times the price for being late.

Forty-five days is not a generous margin on a weekly injection. A delayed prescription renewal, a holiday, a pharmacy backlog or a fortnight of hesitating about whether to continue are all ordinary events that consume it. If you budget for a GLP-1 at the advertised price, budget also for the fact that the advertised price is conditional on never being late, and put the refill date in your calendar rather than in your memory.

Where compounding is still legitimate

It would be wrong to read all of the above as “compounded is banned”. Patient-specific compounding under section 503A did not disappear; what ended was the shortage-driven exemption that allowed it at industrial scale. A compounded preparation made for an individual patient with a documented clinical need the approved product cannot meet — a genuine allergy to an inactive ingredient, for instance, or a dose the manufactured product does not supply — remains a recognised part of pharmacy practice.

The distinction that matters is between a prescription written for you and a product marketed to everybody. If a website offers the same compounded formulation to any adult who completes a questionnaire, that is not patient-specific compounding whatever the checkout page calls it.

What to ask before you hand over a card

• Is this the approved medicine or a compounded version? Ask it in those words and expect a direct answer. If the answer arrives wrapped in “pharmaceutical grade” or “same active ingredient”, it is a compounded version.
• What exactly am I subscribing to? Several programmes bill a recurring membership that continues whether or not medication ships. Read the cancellation window and the refund position before the first charge, not after.
• Who is the prescriber, and are they licensed in my state? A named clinician you can look up is a different proposition from a “medical team”.
• How is the dose supplied? A fixed-dose pen or single-dose vial removes the entire class of measurement error described above. A multi-dose vial and a syringe does not.
• What happens to the price at higher doses? Everyone’s dose escalates. Ask for the price at the dose you will be on in six months, not the one you start at.

If you are taking one of these, protein is the thing to get right

Weight lost on a GLP-1 is not all fat, and appetite suppression makes it easy to under-eat protein badly without noticing. The expert groups put healthy older adults at 1.0 to 1.2 grams of protein per kilogram of body weight a day, rising to 1.2 to 1.5 g/kg for those who are exercising or unwell — figures that are much harder to hit on a suppressed appetite. Our guide to how much protein you actually need, with a calculator for your own body weight, sets out where those numbers come from and what the guidelines will and will not say about timing.

Frequently Asked Questions

Is compounded semaglutide still legal in 2026?

Not as a mass-market product. The shortage-based exemption that permitted it ended on 22 April 2025 for state-licensed 503A pharmacies and 22 May 2025 for 503B outsourcing facilities, and the FDA has since proposed excluding semaglutide from the 503B bulks list on a finding of no clinical need. Patient-specific compounding for an individual with a documented need the approved product cannot meet is a narrower and different situation, and it still exists. A standard formulation sold to anyone who fills in a questionnaire is not that.

When did compounded tirzepatide stop being permitted?

Earlier than semaglutide. The FDA’s period of enforcement discretion ended on 18 February 2025 for 503A state-licensed pharmacies and 19 March 2025 for 503B outsourcing facilities. Tirzepatide came off the shortage list first, so its wind-down ran ahead of semaglutide’s by about two months.

Is compounded semaglutide as safe as Wegovy?

Nobody can tell you that it is, because the study that would answer it has not been done. The FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed, so a compounded version carries no evidence of its own. What exists instead is a reporting signal: 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of 31 May 2026, including hospitalisations the agency links to dosing errors.

Why are there so many dosing errors with compounded GLP-1s?

Because of how the dose is supplied rather than anything about the molecule. Approved products come as pens or single-dose vials with the dose already fixed. A large share of compounded supply arrives as a multi-dose vial plus a syringe, leaving the patient to convert between the concentration in the vial, the units printed on the syringe and the dose written in the instructions. Those are three different scales, and a tenfold error is easy to make.

How much does Wegovy cost without insurance?

From Novo Nordisk’s own NovoCare pharmacy, $349 a month for the 0.25, 0.5, 1, 1.7 and 2.4 mg doses, and $399 a month for Wegovy HD 7.2 mg. New patients pay an introductory $199 a month for the first two fills of 0.25 mg and 0.5 mg, an offer the company says runs through 31 December 2026. The oral form is priced separately at $149, $199 and $299 a month depending on strength.

How much does Zepbound cost without insurance?

Through Lilly’s Self-Pay Journey Program the single-dose vials are $299 a month at 2.5 mg, $399 at 5 mg, and $449 at 7.5, 10, 12.5 and 15 mg. The $449 applies only on the first fill and on refills placed within 45 days of the previous delivery. Outside that window the same vials are $599, $699, $849 and $1,049 respectively. Lilly gives the list price as $499 to $1,086.37 per fill.

What is the 45-day rule on Zepbound pricing?

It is the condition attached to the advertised self-pay price at the four highest doses. Lilly’s footnote states the programme price applies only on first fill and when a prescription is refilled within 45 days of the previous delivery. A late refill at 15 mg moves the price from $449 to $1,049. It is the single most expensive detail in GLP-1 pricing and it is almost never mentioned alongside the headline figure.

What about peptides sold “for research purposes only”?

Treat them as a separate and more dangerous category. The FDA has warned companies illegally selling unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide labelled “for research purposes” or “not for human consumption” while supplying dosing instructions to consumers. Retatrutide, survodutide and mazdutide are investigational; there is no established human dose to follow, and the label disclaiming human use is a legal shield rather than a description of the intended buyer.

The Bottom Line

Two things changed at once, and they point the same way. The legal room that allowed compounded GLP-1s to be sold at scale closed across four dates in 2025, and the FDA has proposed closing it further on the grounds that there is no clinical need. At the same time the price advantage that justified taking the risk has largely disappeared, because both manufacturers now sell the approved product direct at $199 to $449 a month depending on drug and dose.

That combination is unusual and worth naming plainly: the safer option and the cheaper option have converged. If you are being quoted a compounded price today, the honest comparison is no longer against a $1,000 list price. It is against $349 for Wegovy or $449 for Zepbound, from the companies that ran the trials — with a calendar reminder set 45 days out.

Sources

1. U.S. Food and Drug Administration, FDA’s concerns with unapproved GLP-1 drugs used for weight loss — “compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed”; 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of 31 May 2026; dosing errors requiring hospitalisation; counterfeit products; and companies selling unapproved semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labelled “for research purposes” or “not for human consumption”. FDA. Checked 10 September 2026.
2. U.S. Food and Drug Administration, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (page updated 1 April 2026) — end of enforcement discretion: tirzepatide 18 February 2025 (503A) and 19 March 2025 (503B); semaglutide 22 April 2025 (503A) and 22 May 2025 (503B); and that FDA “may still take action regarding violations of any other statutory or regulatory requirements”. FDA. Checked 10 September 2026.
3. U.S. Food and Drug Administration, FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List — proposal on a finding of no clinical need for outsourcing facilities to compound these substances from bulk; comments invited through 29 June 2026. FDA. Checked 10 September 2026.
4. Novo Nordisk, Wegovy self-pay pricing through NovoCare Pharmacy — $199 a month for the first two monthly fills of 0.25 mg and 0.5 mg through 31 December 2026; $349 a month for 0.25, 0.5, 1, 1.7 and 2.4 mg; $399 a month for Wegovy HD 7.2 mg; oral 1.5 mg $149, 4 mg $199, 9 mg and 25 mg $299. NovoCare. Checked 10 September 2026.
5. Eli Lilly and Company, Lilly lowers the price of Zepbound single-dose vials — 2.5 mg $299, 5 mg $399, and 7.5, 10, 12.5 and 15 mg at $449 per month under the Zepbound Self-Pay Journey Program, which “lowers the price of the 7.5 mg, 10 mg, 12.5 mg and 15 mg vials only on first fill and when prescriptions are refilled within 45 days of their previous delivery”; non-programme prices $599, $699, $849 and $1,049. Lilly investor relations. Checked 10 September 2026.
6. Bauer J, Biolo G, Cederholm T, et al. Evidence-Based Recommendations for Optimal Dietary Protein Intake in Older People: A Position Paper From the PROT-AGE Study Group. J Am Med Dir Assoc. 2013;14(8):542-559. PMID: 23867520 — “recommends average daily intake at least in the range of 1.0 to 1.2 g protein per kilogram of body weight per day”, and 1.2-1.5 g/kg for those with acute or chronic disease. PubMed record. Checked 9 September 2026.
7. Deutz NEP, Bauer JM, Barazzoni R, et al. Protein intake and exercise for optimal muscle function with aging: Recommendations from the ESPEN Expert Group. Clinical Nutrition. 2014;33(6):929-936. PMID: 24814383 — “for healthy older people, the diet should provide at least 1.0-1.2 g protein/kg body weight/day”; 1.2-1.5 g/kg where there is acute or chronic illness. PubMed record. Checked 9 September 2026.
8. Eli Lilly and Company, Zepbound cost information — list price of Zepbound given as $499 to $1,086.37 per fill. pricinginfo.lilly.com. Checked 10 September 2026.